HomeHiltonol BackgroundClinical Trials

 
About Oncovir 

 
 
Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.

Oncovir promotes Hiltonol (poly-ICLC) as an experimental viral mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions. 
 
 

Questions or comments? Get in touch with us at:

3203 Cleveland Ave, NW Washington, DC, 20008; asalazar@oncovir.com